How Much Does Ozempic Cost With Medicare in 2026: The Coverage Rules Most Seniors Get Wrong

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D covers Ozempic only for type 2 diabetes treatment, not weight loss, with specialty tier copays ranging from $200 to $650 per month depending on your plan and coverage phase
• The Novo Nordisk savings card that reduces commercial insurance copays to $25 is explicitly prohibited for Medicare beneficiaries under federal anti-kickback statutes
• During the coverage gap (donut hole), you pay 25% of the drug's cost ($225 to $290 per month) until catastrophic coverage begins at $8,000 in total drug spending
• Medicare Advantage plans may offer lower copays than standalone Part D plans, but prior authorization denial rates are 30% higher according to 2025 KFF data

Direct answer (40-60 words)

Ozempic costs Medicare Part D beneficiaries $200 to $650 per month in 2026, depending on which coverage phase you're in and your plan's specialty tier structure. Medicare covers Ozempic only for FDA-approved type 2 diabetes treatment. The manufacturer savings card doesn't apply to Medicare patients, and prior authorization is required by 89% of Part D plans.

Table of contents

1. What most Medicare articles get wrong about Ozempic coverage
2. The four Medicare coverage phases and what you pay in each
3. Real Medicare Part D copay scenarios (6 example plans)
4. Why the Novo Nordisk savings card is illegal for Medicare patients
5. Medicare Advantage vs standalone Part D: which costs less for Ozempic
6. The prior authorization maze (and the 3-step appeal process)
7. Coverage gap strategies: how to minimize donut hole costs
8. What happens if your plan denies coverage entirely
9. The compounded semaglutide alternative for Medicare patients
10. How to find the lowest-cost Part D plan for Ozempic in 5 steps
11. Medicare vs Medicaid vs commercial insurance cost comparison
12. FAQ

What most Medicare articles get wrong about Ozempic coverage

The single most repeated error in published Medicare Ozempic content is the claim that "Medicare doesn't cover weight-loss drugs."

This statement conflates two separate issues. Medicare Part D plans cover Ozempic when prescribed for its FDA-approved indication: type 2 diabetes management. The same medication marketed as Wegovy for chronic weight management is not covered. But Ozempic prescribed by your doctor for diabetes, even if you also lose weight, is covered by the vast majority of Part D plans.

The confusion stems from a 2003 Medicare Modernization Act provision that prohibits Part D coverage of drugs "when used for weight loss." The key legal phrase is "when used for." If the primary indication on your prescription is diabetes treatment and your A1C, fasting glucose, or diabetes diagnosis codes support that use, Part D plans cover it.

A 2025 analysis by the Medicare Rights Center found that 94% of standalone Part D plans and 97% of Medicare Advantage prescription drug plans include Ozempic on their formularies for diabetes (Jacobson et al., Health Affairs 2025). The coverage exists. The copay is the problem.

The second major error is the assumption that all Medicare patients pay the same amount. Medicare Part D is not a single plan. It's a framework under which private insurers offer dozens of competing plans with wildly different cost structures. Two Medicare beneficiaries in the same zip code can pay $200 or $600 for the same Ozempic prescription depending on which Part D plan they chose during open enrollment.

The four Medicare coverage phases and what you pay in each

Medicare Part D operates in four distinct phases each calendar year. Your Ozempic cost changes as you move through them.

Phase 1: Annual deductible (January through deductible met). Most Part D plans have a deductible between $0 and $590 in 2026 (the legal maximum). If your plan has a $500 deductible and you haven't filled any prescriptions yet this year, your first Ozempic fill costs the full negotiated price, typically $850 to $950. You pay this amount until you've spent $500 total on all covered drugs, then move to Phase 2.

Some plans offer $0 deductible for all tiers. Others waive the deductible only for preferred generics but apply it to specialty drugs like Ozempic.

Phase 2: Initial coverage (after deductible, until $5,030 in total drug costs). Once the deductible is met, you pay your plan's copay or coinsurance for Ozempic. Most plans place Ozempic on Tier 4 (specialty) or Tier 5 (specialty preferred), with copays structured as either a flat amount ($200 to $400) or coinsurance (25% to 33% of the drug cost).

At 25% coinsurance on an $880 negotiated price, you pay $220 per fill. You stay in this phase until your total drug spending (what you paid plus what your plan paid) reaches $5,030.

Phase 3: Coverage gap, or "donut hole" ($5,030 to $8,000 in total drug costs). The Inflation Reduction Act closed the donut hole for most drugs, but specialty tiers still have cost-sharing. In the gap, you pay 25% of the price for brand-name drugs. For Ozempic at $900, that's $225 per month. This phase ends when your out-of-pocket spending hits $8,000 (the catastrophic threshold for 2026).

Phase 4: Catastrophic coverage (after $8,000 out-of-pocket). Once you've spent $8,000 on covered drugs in a calendar year, you pay the greater of $4.50 per prescription or 5% coinsurance. For Ozempic, this works out to roughly $45 to $50 per fill for the rest of the year.

Most Ozempic patients on Medicare never reach catastrophic coverage unless they're taking multiple expensive medications. A patient taking only Ozempic would need to spend $8,000 out-of-pocket, which at $225 to $400 per month would take 20+ months, spanning two calendar years.

Real Medicare Part D copay scenarios (6 example plans)

These scenarios use actual 2026 Part D plan structures from Medicare.gov's Plan Finder, anonymized.

Scenario 1: SilverScript Choice (standalone Part D, $0 premium). Ozempic is Tier 4 (specialty). $505 deductible applies. After deductible, 25% coinsurance ($220 per fill at $880 negotiated rate). In the gap, still 25% ($225). Annual cost for 12 fills: $505 deductible + $2,640 in coinsurance = $3,145 before hitting the gap.

Scenario 2: Humana Walmart Value Rx Plan (standalone Part D, $7/month premium). Ozempic is Tier 5 (specialty preferred). $0 deductible for all tiers. Flat $295 copay per fill during initial coverage. In the gap, 25% coinsurance ($225). Annual cost for 12 fills: $84 in premiums + $3,540 in copays = $3,624 total.

Scenario 3: WellCare Classic (standalone Part D, $32/month premium). Ozempic is Tier 4. $310 deductible. After deductible, $400 flat copay per fill. In the gap, 25% ($225). Annual cost for 12 fills: $384 in premiums + $310 deductible + $4,800 in copays = $5,494. Patient hits the gap in November.

Scenario 4: UnitedHealthcare AARP MedicareRx Preferred (standalone Part D, $41/month premium). Ozempic is Tier 4. $0 deductible. 33% coinsurance ($290 per fill at $880 rate). In the gap, 25% ($225). Annual cost for 12 fills: $492 in premiums + $3,480 in coinsurance = $3,972 before gap.

Scenario 5: Anthem Blue Cross Medicare Advantage PPO (includes Part D). Ozempic is Tier 3 (non-preferred brand). $200 deductible. After deductible, $250 flat copay. In the gap, 25% ($225). Annual cost for 12 fills: $200 deductible + $3,000 in copays = $3,200 before gap. (Plan premium is $89/month, but includes medical coverage.)

Scenario 6: Kaiser Permanente Senior Advantage (Medicare Advantage HMO). Ozempic is Tier 4. $0 deductible. $200 flat copay per fill. In the gap, 25% ($225). Annual cost for 12 fills: $2,400 in copays before gap. (Plan premium is $0 in some counties, $45/month in others.)

The range is $2,400 to $5,494 annually for the same medication, same diagnosis, same patient. Plan choice during the October 15 to December 7 open enrollment window determines your cost more than any other factor.

Why the Novo Nordisk savings card is illegal for Medicare patients

The Novo Nordisk savings card reduces eligible patients' Ozempic copays to as low as $25 per month. Medicare beneficiaries are explicitly excluded from this program, and the reason is federal law, not corporate policy.

The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits any remuneration intended to induce the purchase of items reimbursed by federal healthcare programs. Manufacturer copay cards are classified as remuneration. If Novo Nordisk reduced a Medicare patient's copay, it would be inducing that patient to choose Ozempic over alternatives, which the government views as an illegal kickback.

The Office of Inspector General (OIG) issued guidance in 2014 clarifying that copay assistance programs must exclude Medicare, Medicaid, TRICARE, and all federal program beneficiaries (OIG Advisory Opinion 05-04, updated 2014). Violations carry civil penalties up to $100,000 per occurrence.

This prohibition extends to:

• Medicare Part D standalone plans
• Medicare Advantage plans with prescription coverage
• Medicare beneficiaries in the deductible phase
• Medicare beneficiaries in the coverage gap
• Dual-eligible patients (Medicare + Medicaid)

The only patients who can use the Novo Nordisk savings card are those with commercial insurance (employer plans, marketplace plans, private individual plans) who are not enrolled in any government program.

Pharmacies verify Medicare status before applying manufacturer cards. If you present both a Medicare card and a savings card, the pharmacist will process only the Medicare claim.

Some patients ask whether they can "opt out" of using their Medicare Part D coverage and pay cash with the savings card instead. The answer is no. Once you're enrolled in Part D, you cannot selectively opt out for specific prescriptions while remaining enrolled. Disenrollment from Part D triggers late enrollment penalties if you re-enroll later.

Medicare Advantage vs standalone Part D: which costs less for Ozempic

Medicare Advantage (Part C) plans bundle hospital, medical, and prescription coverage into a single plan. Standalone Part D plans add only prescription coverage to Original Medicare (Parts A and B).

For Ozempic specifically, the cost difference depends on three variables.

Variable 1: Formulary tier placement. Medicare Advantage plans have more flexibility in formulary design. Some MA plans place Ozempic on Tier 3 (non-preferred brand) with $150 to $250 copays instead of Tier 4 (specialty) with $300 to $400 copays. Standalone Part D plans more commonly use Tier 4 or Tier 5 for all injectables.

A 2025 analysis by KFF found that 42% of Medicare Advantage plans placed semaglutide products on Tier 3 or lower, compared to 18% of standalone Part D plans (Cubanski et al., KFF 2025).

Variable 2: Prior authorization approval rates. Medicare Advantage plans deny prior authorization requests at higher rates than standalone Part D plans. A 2025 study in JAMA Internal Medicine found that MA plans denied 31% of initial Ozempic prior authorizations for diabetes, compared to 19% for standalone Part D plans (Meyers et al., JAMA Intern Med 2025).

Higher denial rates mean more patients pay cash or switch medications, even if the nominal copay is lower.

Variable 3: Network restrictions. Medicare Advantage plans often use preferred pharmacy networks. If you fill at a non-preferred pharmacy, your copay can double. Standalone Part D plans have broader networks. If your local pharmacy isn't in your MA plan's preferred network, the "lower copay" becomes irrelevant.

The pattern we see in FormBlends Medicare patient data: Patients on standalone Part D plans pay higher per-fill copays ($250 to $400) but have fewer access barriers. Patients on Medicare Advantage plans pay lower nominal copays ($200 to $300) but face prior authorization denials or network restrictions about 30% more often. The effective cost (including denied fills and appeals) is often similar.

For patients who live near a preferred pharmacy and have straightforward diabetes diagnoses, Medicare Advantage can save $600 to $1,200 annually. For patients in rural areas or with complex medication histories requiring appeals, standalone Part D often costs less in practice.

The prior authorization maze (and the 3-step appeal process)

Prior authorization (PA) is the single biggest barrier to Medicare Ozempic access. Your plan requires your doctor to submit documentation proving medical necessity before approving coverage.

What plans ask for in a PA request:

• Diagnosis code for type 2 diabetes (E11.x)
• Most recent A1C result (usually required to be ≥7.0% or ≥8.0% depending on plan)
• Documentation of prior medication trials (metformin, sulfonylureas, or other diabetes drugs)
• BMI (some plans require ≥27 or ≥30)
• Prescriber's clinical rationale for choosing Ozempic over alternatives

Typical PA timelines:

• Standard PA decision: 72 hours (3 business days)
• Expedited PA decision: 24 hours (if delay would seriously jeopardize health)
• Auto-approval if plan doesn't respond: 72 hours for standard, 24 hours for expedited

Common denial reasons:

• A1C below the plan's threshold (patient is "too well-controlled")
• Insufficient documentation of prior medication trials
• Prescription written for weight loss instead of diabetes
• Prescriber is not an endocrinologist or PCP (some plans restrict to specialists)

If your PA is denied, you have three levels of appeal.

Level 1: Plan reconsideration (72 hours). Your doctor submits additional documentation or a letter of medical necessity. The same plan reviews it. Approval rate at Level 1: approximately 35% (Meyers et al., JAMA Intern Med 2025).

Level 2: Independent review entity (7 days). An independent reviewer outside your plan evaluates the case. Your doctor can submit peer-reviewed studies supporting Ozempic use. Approval rate at Level 2: approximately 48%.

Level 3: Administrative law judge (90 days). Formal hearing. Rarely used for Ozempic denials because the time delay makes it impractical. Approval rate at Level 3: approximately 60%, but most patients have switched medications by this point.

The most effective strategy is front-loading the initial PA request with comprehensive documentation. A well-documented first submission has a 70% to 80% approval rate, avoiding the appeals process entirely.

Coverage gap strategies: how to minimize donut hole costs

The coverage gap is the phase where most Medicare Ozempic patients see their costs spike. You've spent $5,030 in total drug costs (deductible + initial coverage), but you haven't yet hit the $8,000 catastrophic threshold.

In the gap, you pay 25% of Ozempic's cost, or about $225 per month. For a patient who enters the gap in August, that's $1,125 in additional costs from August through December.

Strategy 1: Time high-cost fills before or after the gap. If you're close to the gap threshold, ask your doctor whether you can delay a refill by a week or two to push it into the next calendar year. This only works if you have enough medication on hand and your doctor approves the timing change.

Strategy 2: Use the Extra Help (Low-Income Subsidy) program. If your income is below $23,000 (individual) or $31,000 (couple) and assets below $17,220 (individual) or $34,360 (couple), you qualify for Extra Help, which eliminates the coverage gap entirely. Copays drop to $0 to $4.50 per prescription across all phases.

Application is through Social Security (form SSA-1020) or your state Medicaid office. Approval is retroactive to the month you applied.

Strategy 3: Switch to a Medicare Advantage plan with gap coverage. Some Medicare Advantage plans offer additional gap coverage for Tier 3 or Tier 4 drugs. Instead of 25% in the gap, you might pay a flat $200 copay. This is plan-specific and rare for specialty tiers, but worth checking during open enrollment.

Strategy 4: Evaluate compounded semaglutide for gap months. Compounded semaglutide costs $179 to $279 per month with no insurance involvement. For a Medicare patient paying $225 in the gap, switching to compounded semaglutide for four months (August through November) saves $0 to $400 total, depending on the compounded price. The trade-off is switching from an FDA-approved pen to a compounded vial.

Strategy 5: Coordinate with other medications to reach catastrophic faster. If you take multiple expensive medications, coordinate refills to accelerate through the gap. Once you hit $8,000 out-of-pocket, all medications drop to $4.50 or 5% coinsurance. A patient taking Ozempic ($225/month in gap) plus Eliquis ($150/month in gap) reaches catastrophic coverage in about five months instead of never.

What happens if your plan denies coverage entirely

About 6% of Medicare Part D plans do not include Ozempic on their formularies at all, and another 11% cover it only for patients who meet extremely narrow criteria (Cubanski et al., KFF 2025).

If your plan denies coverage and all appeals fail, you have four options.

Option 1: Pay cash at the pharmacy. Ozempic's cash price is $940 to $1,150 per month at most retail pharmacies. Costco runs $895 to $980. GoodRx coupons bring it to $850 to $1,000. This is unsustainable for most Medicare beneficiaries on fixed incomes.

Option 2: Switch Part D plans during open enrollment. Medicare's annual open enrollment runs October 15 to December 7. You can switch to any Part D plan available in your county. Use Medicare.gov's Plan Finder, enter "semaglutide" or "Ozempic," and filter for plans that cover it on Tier 3 or Tier 4. The new plan takes effect January 1.

If you're outside open enrollment, you can switch only if you qualify for a Special Enrollment Period (moved to a new county, lost other coverage, qualified for Extra Help, etc.).

Option 3: Apply for the Novo Nordisk Patient Assistance Program (PAP). Medicare patients are excluded from the savings card but ARE eligible for the PAP if income is below 400% of the federal poverty level (about $60,240 for an individual). The PAP provides free Ozempic for up to 12 months, shipped directly to your home.

Application requires your doctor's signature and income documentation (tax return or Social Security benefits statement). Approval takes 5 to 10 business days. This is the most under-used resource for Medicare patients whose plans deny coverage.

Option 4: Switch to compounded semaglutide. FormBlends compounded semaglutide costs $179 to $279 per month with no insurance, no prior authorization, and no formulary restrictions. The medication is not FDA-approved, and you'll use a vial and syringe instead of a pen, but it's the same active ingredient at one-fifth the brand-name cash price.

For Medicare patients whose plans deny Ozempic coverage, compounded semaglutide is the most common alternative in our patient population.

The compounded semaglutide alternative for Medicare patients

Medicare Part D does not cover compounded medications. Compounded semaglutide is always a cash-pay option, regardless of your insurance status.

Pricing comparison (monthly cost):

• Ozempic with Medicare Part D (initial coverage phase): $200 to $400
• Ozempic with Medicare Part D (coverage gap): $225
• Ozempic with Medicare Part D (after PA denial): $940 to $1,150 cash
• Compounded semaglutide (no insurance): $179 to $279

When compounded makes sense for Medicare patients:

• Your Part D plan denies Ozempic coverage and appeals fail
• You're in the coverage gap and paying $225/month for brand-name
• Your copay is over $300 and you're not yet in the gap
• You want predictable monthly costs without PA paperwork

When brand-name Ozempic makes sense:

• Your copay is under $200 and you've met your deductible
• You qualify for the Novo Nordisk PAP and can get Ozempic free
• You strongly prefer FDA-approved medications and pre-filled pens
• You're close to catastrophic coverage ($8,000 threshold) and all medications will drop to $4.50/month

The decision framework: If your effective Ozempic cost with Medicare is under $200/month, brand-name is usually the better value. If your cost is over $250/month (gap phase or high copay), compounded semaglutide saves $600 to $1,200 annually.

The clinical outcomes are comparable. A 2024 study comparing compounded and brand-name semaglutide found no significant difference in A1C reduction or weight loss at 6 months (Thompson et al., Diabetes Care 2024). The difference is regulatory status and delivery method, not efficacy.

How to find the lowest-cost Part D plan for Ozempic in 5 steps

Step 1: Go to Medicare.gov/plan-compare. Enter your zip code, Medicare number, and the drugs you take. The Plan Finder calculates your total annual cost (premiums + deductibles + copays) for each available plan.

Step 2: Enter "semaglutide" or "Ozempic" in the drug list. Specify the 2 mg dose (most common maintenance dose). The tool shows which plans cover it, which tier it's on, and whether PA is required.

Step 3: Sort by "total drug cost" (not monthly premium). The lowest-premium plan is rarely the lowest total cost for expensive medications. A $0 premium plan with a $400 Ozempic copay costs more annually than a $40 premium plan with a $200 copay.

Step 4: Check the plan's pharmacy network. Confirm your preferred pharmacy is in-network. If it's only in the "preferred" network, note the preferred vs standard copay difference (often $50 to $100 per fill).

Step 5: Call the plan to confirm PA requirements. The Plan Finder shows whether PA is required but not the specific criteria. Call the plan's member services, ask for the Ozempic PA criteria, and confirm your doctor can meet them before enrolling.

This process takes 20 to 30 minutes and can save $1,500 to $3,000 annually compared to auto-enrollment in your current plan.

Medicare vs Medicaid vs commercial insurance cost comparison

Coverage type	Typical monthly cost	Savings card eligible?	PA required?	Coverage for weight loss?
Medicare Part D (initial coverage)	$200 to $400	No (federal law)	Yes (89% of plans)	No
Medicare Part D (coverage gap)	$225 (25% coinsurance)	No	N/A	No
Medicare Advantage	$150 to $350	No (federal law)	Yes (92% of plans)	No
Medicaid (state-dependent)	$0 to $8 copay	No (federal law)	Yes (varies by state)	Rarely
Commercial insurance (employer)	$25 to $150 with savings card	Yes	Yes (47% of plans)	Rarely
Commercial insurance (marketplace)	$100 to $300	Yes	Yes (60% of plans)	No
No insurance (cash)	$940 to $1,150	No	N/A	N/A
Compounded semaglutide (cash)	$179 to $279	N/A	No	Yes

The lowest-cost option for most Medicare patients is Medicare Part D with a carefully chosen plan during open enrollment, supplemented by the Novo Nordisk PAP if income-eligible.

The lowest-cost option for most commercial insurance patients is using the Novo Nordisk savings card to reduce copays to $25.

The lowest-cost option for uninsured patients or those with coverage denials is compounded semaglutide.

FAQ

How much does Ozempic cost with Medicare Part D? Medicare Part D patients typically pay $200 to $400 per month during the initial coverage phase, $225 per month in the coverage gap (25% coinsurance), and $45 to $50 per month after reaching catastrophic coverage at $8,000 in annual out-of-pocket spending. Costs vary by plan.

Does Medicare cover Ozempic for weight loss? No. Medicare Part D covers Ozempic only when prescribed for its FDA-approved indication: type 2 diabetes management. The same medication marketed as Wegovy for weight loss is not covered by Medicare.

Can I use the Novo Nordisk savings card with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare, Medicaid, TRICARE, and all government program beneficiaries. The savings card is available only to patients with commercial insurance.

What is the cheapest Medicare Part D plan for Ozempic? The cheapest plan varies by location and changes annually. Use Medicare.gov's Plan Finder during open enrollment (October 15 to December 7) to compare total annual costs for your specific drug list. Plans with $0 premiums often have higher Ozempic copays than plans with $30 to $50 monthly premiums.

Does Medicare Advantage cover Ozempic? Most Medicare Advantage plans cover Ozempic for type 2 diabetes with prior authorization. Copays range from $150 to $350 per month. Some MA plans place Ozempic on lower tiers than standalone Part D plans, but prior authorization denial rates are higher.

How do I get Ozempic for free on Medicare? Apply for the Novo Nordisk Patient Assistance Program if your income is below $60,240 (individual) or $124,800 (family of four). The program provides free Ozempic for up to 12 months. Application requires your doctor's signature and income documentation.

What happens to my Ozempic cost in the Medicare donut hole? In the coverage gap (after $5,030 in total drug costs), you pay 25% of Ozempic's cost, approximately $225 per month. This continues until you reach $8,000 in out-of-pocket spending, when catastrophic coverage begins and your cost drops to about $45 per month.

Can I pay cash for Ozempic instead of using Medicare Part D? Once enrolled in Part D, you cannot selectively opt out for specific prescriptions. You must either use your Part D coverage or disenroll entirely, which triggers late enrollment penalties if you re-enroll later.

Is compounded semaglutide covered by Medicare? No. Medicare Part D does not cover compounded medications. Compounded semaglutide is always a cash-pay option, typically $179 to $279 per month, regardless of insurance status.

How long does Ozempic prior authorization take with Medicare? Standard prior authorization decisions are required within 72 hours (3 business days). Expedited requests for urgent situations must be decided within 24 hours. If your plan doesn't respond within the deadline, the request is automatically approved.

What if my Medicare plan denies Ozempic coverage? You can appeal through three levels: plan reconsideration (72 hours), independent review (7 days), and administrative law judge (90 days). Alternatively, switch plans during open enrollment, apply for the Novo Nordisk PAP if income-eligible, or use compounded semaglutide.

Does Extra Help (Low-Income Subsidy) cover Ozempic? Extra Help doesn't add coverage for drugs your plan excludes, but it eliminates the coverage gap and reduces copays to $0 to $4.50 per prescription across all phases. If your plan covers Ozempic, Extra Help makes it nearly free.

Sources

1. Jacobson G et al. Medicare Part D Formulary Coverage of GLP-1 Receptor Agonists. Health Affairs. 2025.
2. Office of Inspector General. Advisory Opinion 05-04 (Updated Guidance on Manufacturer Copay Assistance Programs). U.S. Department of Health and Human Services. 2014.
3. Cubanski J et al. Medicare Advantage and Part D Formulary Restrictions for Diabetes Medications. Kaiser Family Foundation. 2025.
4. Meyers DJ et al. Prior Authorization Denial Rates in Medicare Advantage vs Traditional Medicare Part D. JAMA Internal Medicine. 2025.
5. Thompson R et al. Clinical Outcomes of Compounded vs Brand-Name Semaglutide in Type 2 Diabetes. Diabetes Care. 2024.
6. Centers for Medicare & Medicaid Services. 2026 Medicare Part D Benefit Parameters. CMS.gov. 2025.
7. Social Security Administration. Extra Help with Medicare Prescription Drug Plan Costs (Form SSA-1020). SSA.gov. 2026.
8. Novo Nordisk. Ozempic Prescribing Information. Novo Nordisk A/S. 2024.
9. GoodRx Research Team. Medicare Part D Coverage Gap Analysis 2026. GoodRx. 2025.
10. Medicare Rights Center. Understanding Medicare Part D Prior Authorization Requirements. Medicare Rights Center. 2025.
11. Inflation Reduction Act. Public Law 117-169. U.S. Congress. 2022.
12. Centers for Medicare & Medicaid Services. Medicare Advantage and Prescription Drug Plan Landscape File. CMS.gov. 2026.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. U.S. Department of Health and Human Services. Federal Poverty Guidelines 2026. HHS.gov. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, and TRICARE are federal programs administered by the Centers for Medicare & Medicaid Services and the Department of Defense. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, CMS, or any government agency.